Health
Moderna doses first patients in COVID-19 vaccine booster trial – The Science Board
Moderna has dosed the first patients in its study of modified COVID-19 vaccines, designed to address the potential need for vaccine booster candidates.
The new candidate, messenger RNA (mRNA)-1273.351, encodes the prefusion stabilized spike protein of the SARS-CoV-2 variant B.1.351, first identified in South Africa, and is being assessed as a booster vaccine to increase the response to emerging SARS-CoV-2 variants. The company is also investigating a second, multivalent candidate, mRNA-1273.211, that is a combination of mRNA-1273 and mRNA-1273.351.
Through a phase II clinical trial amendment, the company will enroll 60 participants previously vaccinated…
-
General11 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News21 hours agoRainbow Beach surfer’s untold 7/7 story
-
Noosa News11 hours agoWoman airlifted to Brisbane hospital after big cat mauling at south-east Queensland zoo near Toowoomba
-
Noosa News11 hours agoUnvaccinated horse dies from Hendra virus as Queensland records first case in three years